• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

    3/28/24 6:00:00 AM ET
    $SNDX
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNDX alert in real time by email

    VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024.

    "Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company's development and growth," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "His experience and leadership in leading multiple development programs through to global regulatory approval will support our efforts to rapidly advance our ‘5 by 5' programs into clinical studies and our continued pipeline expansion of novel antibody-drug conjugates and multispecific antibodies in the years ahead."

    "Dr. Gallagher brings more than 20 years of experience in the pharmaceutical and biotechnology sectors in North America and Europe as a leader in drug development in the oncology field, and we are very pleased to welcome him as a member of our board of directors," said Dr. Susan Mahony, lead independent director of Zymeworks.

    "Zymeworks' dedication to seeking to improve the standard of care for patients with difficult-to-treat cancers and other serious diseases is evident in their innovative approach in developing next-generation product candidates. I am delighted to join the Zymeworks' team and look forward to sharing my experience as the company advances development of these novel therapies into clinical studies," said Dr. Gallagher. "Building on the company's progress to date, we have the potential to deliver differentiated therapies and potentially make a meaningful impact on patient lives."

    Dr. Gallagher currently serves as President and Head, Research & Development at Syndax Pharmaceuticals (NASDAQ:SNDX). As a physician-scientist, trained gynecological oncologist, and research scientist working in cancer biology, he has extensive drug development experience from late pre-clinical to translational research and marketing approval. Dr. Gallagher has directly led or overseen multiple medical product approvals globally, including biologics and small molecules, across several therapeutic areas. Before joining Syndax Pharmaceuticals in 2023, Dr. Gallagher was Head of Development and Chief Medical Officer of AbbVie. He has also served as Vice President and Head, Global Oncology Development at AbbVie and Head of Development, Oncology, and Inflammation at Amgen. Before joining Amgen, he spent 10 years at Novartis in both Europe and the United States, and also held roles at Astex Therapeutics and AstraZeneca. He received an M.D. from Trinity College Dublin and a Ph.D. in Cancer Biology from the University of Birmingham.

    Dr. Gallagher was also appointed to serve as a member of the research and development committee of the board of directors.

    About Zymeworks Inc.

    Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to potential therapeutic effects and commercial potential of zanidatamab and Zymeworks' other product candidates; Zymeworks' clinical development of its product candidates and enrollment in its clinical trials; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as "plan", "believe", "expect", "may", "continue", "anticipate", "potential", "will", "progress", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; and the factors described under "Risk Factors" in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedar.com). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

    Investor inquiries:

    Shrinal Inamdar

    Director, Investor Relations

    (604) 678-1388

    [email protected]

    Media inquiries:

    Diana Papove

    Senior Director, Corporate Communications

    (604) 678-1388

    [email protected]



    Primary Logo

    Get the next $SNDX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNDX
    $ZYME

    CompanyDatePrice TargetRatingAnalyst
    Syndax Pharmaceuticals Inc.
    $SNDX
    7/10/2025$18.00Buy
    Goldman
    Zymeworks Inc.
    $ZYME
    5/20/2025Buy
    TD Cowen
    Zymeworks Inc.
    $ZYME
    12/16/2024$18.00Neutral → Overweight
    Analyst
    Zymeworks Inc.
    $ZYME
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    Zymeworks Inc.
    $ZYME
    11/1/2024$12.00Overweight → Equal Weight
    Wells Fargo
    Syndax Pharmaceuticals Inc.
    $SNDX
    10/24/2024$37.00Buy
    UBS
    Syndax Pharmaceuticals Inc.
    $SNDX
    6/28/2024$37.00Buy
    Jefferies
    Syndax Pharmaceuticals Inc.
    $SNDX
    1/31/2024$36.00 → $23.00Sector Outperform → Sector Perform
    Scotiabank
    More analyst ratings

    $SNDX
    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      5/19/25 6:35:05 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      5/19/25 4:04:07 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      5/19/25 4:03:03 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Syndax Pharmaceuticals with a new price target

      Goldman initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      7/10/25 9:00:59 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Zymeworks

      TD Cowen initiated coverage of Zymeworks with a rating of Buy

      5/20/25 8:13:34 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Analyst with a new price target

      Analyst upgraded Zymeworks from Neutral to Overweight and set a new price target of $18.00

      12/16/24 6:40:30 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    $ZYME
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by Zymeworks Inc.

      SCHEDULE 13D - Zymeworks Inc. (0001937653) (Subject)

      6/27/25 6:14:18 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Zymeworks Inc.

      8-K - Zymeworks Inc. (0001937653) (Filer)

      6/27/25 4:15:34 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

      8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)

      6/26/25 8:54:52 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025 the Company granted inducement awards to purchase up to 228,400 shares of common stock to 14 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About Synd

      7/2/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

      – PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA's RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia – NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj® (revumenib) for the treatment of relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML). The sNDA is being re

      6/24/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

      – Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed with 67% (29/43) CR rate, 88% (38/43) ORR, and 100% (37/37) MRD negativity among responders – – Enrollment underway in pivotal Ph 3 EVOLVE-2 trial evaluating revumenib with ven/aza in newly diagnosed mNPM1 AML patients unfit for intensive chemotherapy – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the BEAT AML trial of revumenib

      6/12/25 12:02:01 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    $ZYME
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

      Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

      11/18/24 9:22:42 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc exercised 5,086,480 in-the-money shares at a strike of $0.00 and covered exercise/tax liability with 41 shares (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      6/27/25 5:50:21 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      5/19/25 6:35:05 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

      4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

      5/19/25 4:04:07 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    $ZYME
    Leadership Updates

    Live Leadership Updates

    See more
    • Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

      - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa

      5/12/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

      VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

      4/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

      VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. With a proven track record in investment management gained over more than two de

      2/18/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 9:00:57 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 4:27:20 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zymeworks Inc.

      SC 13G - Zymeworks Inc. (0001937653) (Subject)

      11/13/24 4:30:24 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNDX
    $ZYME
    Financials

    Live finance-specific insights

    See more
    • Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference call with management today at 4:30 p.m. Eastern Time (ET) VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to imp

      5/8/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

      – $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, toda

      5/5/25 4:01:00 PM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 5, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alt

      4/28/25 7:00:00 AM ET
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care